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Many researchers have shown that pretreatment plasma fibrinogen levels are closely correlated with the
prognosis of patients with lung cancer (LC). In this study, we thus performed a meta-analysis to systematically
assess the prognostic value of pretreatment plasma fibrinogen levels in LC patients.
A computerized systematic search in PubMed, EMBASE, Web of Science and China National Knowledge
Infrastructure (CNKI) was performed up to March 15, 2018. Studies with available data on the prognostic value
of plasma fibrinogen in LC patients were eligible for inclusion. The pooled hazard ratios (HRs) and odd ratios
(ORs) with 95% confidence intervals (CIs) were used to evaluate the correlation between pretreatment plasma
fibrinogen levels and prognosis as well as clinicopathological characteristics.
A total of 17 studies with 6,460 LC patients were included in this meta-analysis. A higher pretreatment plasma
fibrinogen level was significantly associated with worse overall survival (OS) (HR: 1.57; 95% CI: 1.39-1.77;
p=0.001), disease-free survival (DFS) (HR: 1.53; 95% CI: 1.33-1.76; p=0.003), and progression-free survival (PFS)
(HR: 3.14; 95% CI: 2.15-4.59; po0.001). Furthermore, our subgroup and sensitivity analyses demonstrated that
the pooled HR for OS was robust and reliable. In addition, we also found that a higher fibrinogen level
predicted advanced TNM stage (III-IV) (OR=2.18, 95% CI: 1.79-2.66; po0.001) and a higher incidence of lymph
node metastasis (OR=1.74, 95% CI: 1.44-2.10; p=0.02).
Our study suggested that higher pretreatment plasma fibrinogen levels predict worse prognoses in LC patients.
KEYWORDS: Pretreatment Plasma Fibrinogen; Lung Cancer; Prognosis; Meta-Analysis.
’ INTRODUCTION
Lung cancer (LC) remains a major cancer-associated cause
of death worldwide. LC falls into either non-small cell lung
cancer (NSCLC) or small cell lung cancer (SCLC), with NSCLC
accounting for nearly 85% of incidents (1,2). Although there
have been great advances in LC therapies, including surgery,
chemoradiotherapy and molecular targeted drugs during the
past decade, LC patients still have rather low 5-year survival
rates (o18%) (2). Disease recurrence and distant metastasis
play a critical role in deteriorating the prognosis of LC
patients (3-5). To date, several clinicopathological character-
istics have been used to predict recurrence, distant metastasis
and oncological survival in LC patients, such as differentia-
tion grade, tumor location and TNM stage (6). The TNM
staging system established based on the Union for Inter-
national Cancer Control (UICC) and the International
Association for the Study of Lung Cancer (IASLC) TNM
classification is of great importance and usefulness in
predicting oncological prognoses and guiding individual
treatment, but the overall survival (OS) of NSCLC patients
varies widely, even for patients with the same TNM stage (6).
Therefore, identifying novel reliable biomarkers for obtaining
additional prognostic information on LC is essential, espe-
cially robust, economical, and easily accessible biomarkers.
An increasing amount of evidence has shown that there is
a close association between the activation of coagulation and
fibrinolysis and cancer invasion, angiogenesis and metastasis
(7-13). Additionally, numerous clinical studies suggested
that hemostatic abnormalities and many hemostasis markers
closely correlated with tumor stage and the oncological
long-term outcomes of cancer patients (14). Fibrinogen, as a
molecule produced by the liver in response to cytokine stimu-
lation, is a key element of the coagulation system. Many
studies have reported that the pretreatment plasma fibrinogen
level was significantly associated with the tumor pathologicalDOI: 10.6061/clinics/2020/e993
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stage and response to therapy and could act as a negative
predictor of prognosis in LC patients (2,6,14-26). Nevertheless,
the weight of its prognostic value in LC is still debated since
many of the studies investigating the prognostic value of
fibrinogen enrolled only small sample sizes, suggesting that
their conclusions may have low statistical power. Therefore,
in this study, we performed a systematic review and meta-
analysis of the previously published literature to comprehen-
sively assess the prognostic value of pretreatment plasma
fibrinogen levels in LC patients.
’ MATERIALS AND METHODS
Study selection
We systemically searched the accessible databases, includ-
ing PubMed, Web of Science, EMBASE and China National
Knowledge Infrastructure (CNKI), to identify eligible studies
published up to March 15, 2018. Three key search items were
used during this process: (fibrinogen or hyperfibrinogen-
emia), (lung cancer/carcinoma or pulmonary cancer/carci-
noma) and (prognosis or prognostic or survival or outcome).
The search strategy used in PubMed was as follows:
search ((fibrinogen[Title/Abstract]) OR hyperfibrinogenemia
[Title/Abstract]) AND ((((lung cancer[Title/Abstract]) OR
lung carcinoma[Title/Abstract]) OR pulmonary cancer[Title/
Abstract]) OR pulmonary carcinoma [Title/Abstract]) AND
((((prognosis[Title/Abstract]) OR prognostic[Title/Abstract])
OR survival[Title/Abstract]) OR outcome[Title/Abstract]).
Additionally, we manually checked the reference lists in
relevant reviews and retrieved studies to identify additional
potentially eligible studies.
Inclusion and exclusion criteria
The inclusion criteria were as follows: (1) clinical study
focusing on exploring the prognostic value of pretreatment
plasma fibrinogen in LC. (2) Hazard ratios (HRs) with
95% confidence intervals (CIs) for survival outcomes were
presented directly, including OS and/or disease-free survival
(DFS) and progression-free survival (PFS), or these values
could be obtained by analyzing the Kaplan–Meier (KM) curve
provided in the eligible studies. Otherwise, the publications
were excluded if they were letters, reviews, duplicates, studies
without available HRs for OS, DFS or PFS, and studies not
involving the association between pretreatment fibrinogen
and prognosis in LC.
Data collection and quality assessment
Two authors extracted the relevant data in an independent
manner. The extracted data included the first author, publi-
cation year, country, recruitment period, median age, study
sample size, histological type of LC, tumor TNM stage, cut-
off values for high fibrinogen level, treatment type, follow-up
time, HRs with 95% CIs for survival outcomes, and analysis
type. During this process, any discrepancies were resolved
by discussion among all the authors.
In this meta-analysis, we applied the Newcastle–Ottawa
Scale (NOS) score to evaluate the quality of each included
study (27). The NOS criteria contain eight items that are cate-
gorized into three domains, including selection, comparability,
and exposure. A maximum of one star is awarded to each item
with high quality in selection and exposure, while the item
related to comparability can be given a maximum of two stars.
The NOS score ranges from zero to nine stars, and studies with
at least 6 stars were considered to have high quality.
Statistical analysis
The combined HRs and their corresponding 95% CIs were
calculated to assess the relationship between pretreatment
plasma fibrinogen and survival outcomes. The combined
odds ratios (ORs) and their corresponding 95% CIs were
used to quantitatively determine the link between plasma
fibrinogen and the clinicopathological parameters of patients
with LC. The coexistence of HR or OR41 (low fibrinogen as
reference), 95% CI not overlapping 1, and p-value o0.05
indicated worse OS and more unfavorable clinicopathologi-
cal parameters. We assessed the statistical heterogeneity
across the studies using Cochran’s Q test and Higgins
I2 statistic. A random-effects model was used to calculate the
parameters when there was significant heterogeneity across
studies (I2450% indicated high heterogeneity). Otherwise,
a fixed-effects model was applied. Subgroup analysis, strati-
fied by country, sample size, TNM stage, cut-off value, treat-
ment type, starting time of recruitment period and analysis
type, was performed to investigate the potential sources of
heterogeneity and to concurrently test the reliability of the
total pooled results. In addition, we performed sensitivity
analysis to further test the robustness of the total pooled
results by the sequential omission of individual studies.
Publication bias was evaluated using Begg’s funnel plots
(28) and Egger’s test (29). If one of the two tests suggested
that obvious publication bias existed among the included
studies, the trim-and-fill method was applied to determine
whether the publication bias significantly affected the
robustness and reliability of the pooled results. All statistical
manipulations in this meta-analysis were carried out using
Stata 12.0 software (Stata Corporation, College Station, TX),
and a p-value 40.05 was used as the threshold of statistical
significance.
’ RESULTS
Study identification
The study identification process is summarized in Figure 1.
A total of 198 articles were retrieved from the PubMed,
EMBASE, Web of Science and CNKI databases in the initial
search. Among them, a total of 23 duplicated articles were
excluded using EndNote X7 software. The remaining 175 pub-
lications were further assessed by checking the titles and
abstracts, and 136 articles were excluded because they were
reviews, comments, conference abstracts, cell/animal experi-
ments or had irrelevant topics. Subsequently, a total of
39 studies were evaluated by screening their full texts, and
22 studies were excluded since they did not provide sufficient
data. Ultimately, 17 eligible studies were included in this
meta-analysis (2,6,14-26,30,31).
Study characteristics and quality
Our meta-analysis included a total of 6,460 patients from
China (n=15) (2,6,12,14,16-23,25,26,31), Turkey (n=1) (15),
and Korea (n=1) (30). Of all the included studies, 2 studies
enrolled patients with SCLC (14,31), 14 studies enrolled
patients with NSCLC (2,6,16-26,30) and 1 study enrolled a
mixed population (15). There were inconsistencies in the cut-
off values of the high plasma fibrinogen level among the
included studies. More information on the main character-
istics of the 17 included studies is summarized in Table 1.
With respect to the quality assessment, all of the included
studies had scores ranging from 6 to 8, indicating that they
were of high quality (Table 2).
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Meta-analysis
Association between fibrinogen level and prognosis
in LC. Of the included studies, 16 studies reported OS
(2,6,14-17,19-26,30,31), four studies referred to DFS (17,18,
23,24) and 3 studies involved PFS (2,14,16). From the pooled
results, we found that a higher pretreatment plasma fib-
rinogen level was significantly associated with worse OS
(HR: 1.57; 95% CI: 1.39-1.77; p=0.001; Figure 2), DFS (HR:
1.53; 95% CI: 1.33-1.76; p=0.003; Figure 3), and PFS (HR: 3.14;
95% CI: 2.15-4.59; po0.001; Figure 4).
Association between fibrinogen level and clinico-
pathological parameters in LC. In this meta-analysis,
sufficient data were available for analyzing the association
between the fibrinogen level and several clinicopatholo-
gical parameters, including sex (2,6,14,16-18,20,24), age
(2,6,14,17,18,20,24), lymph node metastasis (2,6,16-18,20,
24) and TNM stage (2,6,17,18,20,24). We found that a
higher fibrinogen level was significantly related to more
advanced TNM stage (III-IV) (OR=2.18, 95% CI: 1.79-2.66;
po0.001; Figure 5A) and a higher frequency of lymph
node metastasis (OR=1.74, 95% CI: 1.44-2.10; p=0.02;
Figure 5B). However, our results showed that there were
no significant associations between the plasma fibrin-
ogen level and sex (OR=1.43, 95% CI: 0.92-2.21; p=0.08;
Figure 5C) or age (OR=1.23, 95% CI: 1.00-1.52; p=0.11;
Figure 5D).
Subgroup and sensitivity analyses
To investigate the possible sources of heterogeneity for
the pooled HR of OS, subgroup analysis was performed
according to country, sample size, recruitment time, cut-off
value, treatment type, histological type and analysis type.
From the results, we observed that significant heterogeneity
did not continuously exist in the subgroups of sample size,
recruitment period and treatment type (Figure 6), suggesting
that they might partly explain the sources of heterogeneity in
our meta-analysis. In addition, the results of all the subgroup
analyses showed that the pooled HRs for OS were still more
than 1, and their CIs did not overlap 1 (Figure 6), indicating
that our pooled result regarding OS was robust and reliable.
Moreover, our sensitivity analysis showed that the pooled
HRs for OS were not altered significantly when individual
studies were omitted in each step, which further demon-
strated the stability and dependability of our pooled result
regarding OS (Figure 7).
Evaluation of publication bias
Begg’s test and Egger’s test were used to evaluate
publication bias for OS. Our results showed that Begg’s
funnel plot appeared asymmetric (Figure 8A), and a p-value
o0.05 was obtained in Egger’s test, indicating that sig-
nificant publication bias existed among these studies explor-
ing the association between the fibrinogen level and OS
in LC. To evaluate the degree of the influence that the
publication bias had on the dependability of the pooled HR
for OS, the trim-and-fill method was used in this analysis.
The results showed that the adjusted funnel plot became
Figure 1 - Flow diagram of the literature identification process.
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symmetric (Figure 8B). More importantly, from the results,
we found that the adjusted pooled HR for OS was still more
than 1, and its corresponding CI did not overlap 1. Thus, the
results of the trim-and-fill method verified that the publica-
tion bias did not significantly affect the reliability of the
pooled result regarding the link between higher fibrinogen
levels and worse OS. Because there were less than 10 eligible
studies that reported DFS/RFS, PFS and clinicopathologi-
cal parameters, it was statistically insignificant to perform
Begg’s test and Egger’s test for assessing publication bias
among the eligible studies.
’ DISCUSSION
The association between pretreatment plasma fibrinogen
levels and prognosis has been investigated in a variety of
malignant tumors, including LC. However, no meta-analyses
have been conducted to systematically assess the correlation
between the plasma fibrinogen level and prognosis as well as
the clinicopathological characteristics of LC patients. To the
best of our knowledge, this study is the first meta-analysis to
systematically evaluate the prognostic value of pretreatment
plasma fibrinogen levels in LC.
In this meta-analysis, a total of 17 eligible studies were
finally included, of which 14 focused on NSCLC, 2 focused
on SCLC and 1 focused on the mixed populations of NSCLC
and SCLC. We found that a higher fibrinogen level was
significantly associated with worse OS, DFS and PFS in LC
patients. Furthermore, our subgroup analysis and sensitivity
analysis verified the robustness and reliability of our pooled
HR for OS. In particular, the multivariate analysis of the
subgroups showed that the pooled HR for OS continued to
be over 1, with its CI not overlapping 1, which indicated that
the pretreatment plasma fibrinogen level may be an inde-
pendent prognostic factor for LC patients. In addition, we
also found that a higher fibrinogen level was significantly
related to advanced TNM stage and a higher frequency of
lymph node metastasis.
Several biological mechanisms may explain the prognostic
significance of higher pretreatment plasma fibrinogen levels
in LC patients. First, fibrinogen is a biomarker that couldTa
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Table 2 - The Newcastle-Ottawa Scale (NOS) quality assessment
of the eligible studies.
Study ID Selection Comparability Exposure/
Outcome
Total
score
Altiay et al. (15)    6
Chen et al. (2)    7
Fan et al. (31)    7
Gu et al. (16)    6
Huang et al. (17)    6
Jiang et al. (18)    6
Kim et al. (30)    7
Li et al. (20)    6
Li et al. (19)    6
Ma et al. (21)    6
Qi et al. (22)    7
Sheng et al. (23)    6
Wang et al. (24)    6
Zeng et al. (6)    6
Zhang et al. (25)    6
Zhu et al. (26)    6
Zhu et al. (14)    6
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Figure 2 - Forest plot of the hazard ratio (HR) for the association between the plasma fibrinogen level and overall survival (OS) in
patients with lung cancer.
Figure 3 - Forest plot of the hazard ratio (HR) for the association between the plasma fibrinogen level and disease-free survival (DFS) in
patients with lung cancer.
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Figure 4 - Forest plot of the hazard ratio (HR) for the association between the plasma fibrinogen level and progression-free survival
(PFS) in patients with lung cancer.
Figure 5 - Forest plot of the odds ratios (ORs) for the association of the plasma fibrinogen level with TNM stage (A), lymph node
metastasis (B), sex (C) and age (D).
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reflect the status of the tumor-associated inflammatory
response (32). Many tumor growth and metastasis-enhancing
events always occur during the tumor-associated inflamma-
tory response, such as the remodeling of the extracellular
matrix, the induction of angiogenesis, the inhibition of
apoptosis, the enactment of immunosuppressive effects, the
stimulation of DNA damage and the increased release of
cytokines and inflammatory mediators (33). For instance, an
animal experiment showed that clearing the fibrinogen in
circulation could inhibit the formation of pulmonary metas-
tases (9), at least suggesting that fibrinogen could reflect a
status availing tumor progression. Second, fibrinogen could
Figure 6 - Subgroup analysis of exploring the possible sources of heterogeneity for the pooled HR for OS.
Figure 7 - Sensitivity analyses of assessing the robustness of the pooled HR for OS.
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bind to some growth factors, such as vascular endothelial
growth factor and fibroblast growth factor, and facilitate
these growth factors binding to their receptors on the tumor
cell surface, which plays a crucial role in contributing to
tumor proliferation and angiogenesis (34). Third, fibrinogen
deposition could promote thrombosis by strengthening the
interaction of cancer cells and platelets, assisting tumor cells
in escaping from the killing effects of natural killers (12).
Overall, these mechanical studies largely increased the
reliability of our findings in this meta-analysis.
Apart from the interesting findings, our analysis has
several limitations as well. First, studies published in only
English and Chinese were included, and studies published in
other languages were not considered, which may introduce
publication bias. Second, the estimated HR was abstracted
from the KM survival curve due to a lack of original data,
likely causing some statistical errors and affecting the preci-
sion of the estimation. Third, the included studies had
inconsistent TNM stages and different accrual periods,
therefore leading to some heterogeneity in our meta-analysis.
Fourth, the majority of the included studies were conducted
in China, so more clinical studies should be performed to
assess the association between plasma fibrinogen and the
prognosis of LC patients from other regions. There may be
three potential reasons why most of the included studies
were performed in China. First, LC is the leading cause of
cancer-related death, and its incidence and mortality in
China have substantially increased in recent years as a conse-
quence of lifestyle diversity and socioeconomic development
(35). In particular, lung cancer-associated mortality in China
is higher than that in most countries (35). Thus, it is likely
that more Chinese researchers focused on exploring novel
reliable biomarkers for predicting prognosis and optimizing
individualized therapy for patients with LC. Second, we
performed the literature selection in this meta-analysis with
language restrictions of English and Chinese since we are
not fluent in other languages. Thus, there is a possibility that
the language restrictions in this meta-analysis probably
excluded some eligible studies published in other languages
and subsequently increased the risk of bias, which may also
partly account for why most of the included studies were
performed in China. Third, in this meta-analysis, the publi-
cation bias assessment suggested that there was significant
publication bias, and the trim-and-fill analysis indicated that
7 studies may not be permitted for publication owing to the
negative results on the prognostic value of the pretreatment
plasma fibrinogen level in patients with LC. It may be coin-
cidental that the 7 studies with negative results were perfor-
med in other countries, which may partly explain why only
2 studies from other countries were included as well. Fifth,
the cut-off values for high fibrinogen levels differed across
the included studies, ranging from 3.3 and 5.8, which pro-
bably also introduced heterogeneity into our meta-analysis.
Further studies are needed to determine an optimal cut-off
value that provides more precise guidance for individual
treatment. Sixth, only two eligible studies with small sample
sizes provided available data regarding the association
between the fibrinogen level and prognosis in SCLC. Hence,
more high-quality studies with larger sample sizes are
needed to further investigate the association between the
fibrinogen level and prognosis in SCLC.
In conclusion, our study showed that high pretreatment
plasma fibrinogen levels predicted a worse prognosis in LC.
However, more prospectively well-designed studies are
needed to further confirm this conclusion due to some
aforementioned limitations.
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